Anodal frontal tDCS for chronic cluster headache treatment: a proof-of-concept trial targeting the anterior cingulate cortex and searching for nociceptive correlates

Table 1 Clinical characteristics of patients included in the analysis

Patients	Age (years)	Gender	CH Side	Baseline weekly attack frequency	CH duration (years)	Chronic phase duration (years)	Ongoing prophylaxis at time of tDCS
1	56	F	R	5	6	2	verapamil - lithium
2	35	M	R/L	30	17	8	verapamil - lithium
3	48	M	R	12	13	13	verapamil - lithium
4	60	M	L	39	9	9	verapamil- clomipramine
5	51	M	L	4	10	10	none
6	46	M	R	7	13	3	carbamazepine - amitriptyline
7	55	M	R	9	20	16	verapamil
8	57	M	L	13	?	?	none
9	56	M	R	13	9	9	duloxetine
10	50	M	R/L	11	18	18	clomipramine
11	41	M	R	12	1.5	1.5	none
12	29	M	R	5	4	4	lithium
13	57	M	L	16	21	18	topiramate
14	50	F	L	4	2.5	2.5	lithium carbonate
15	48	M	L	8	5	3	verapamil - lithium - melatonin
16	59	F	R	60	22	14	ONS
17	63	M	R	17	15	1	verapamil
18	42	M	R	8	16	16	verapamil
19	30	M	R	5	11	5	verapamil - lithium - topiramate
20	53	M	R	18	40	40	verapamil
21	59	M	L	25	14	14	none
22	34	M	L	14	15	15	none
23	40	M	R	22	7	4	verapamil
Mean	48,65				14,25	11,10
SD	9,97				8,03	8,85

CH cluster headache, R right, L left, M male, F female, ONS percutaneous occipital nerve stimulation, tDCS transcranial direct current stimulation

ISSN: 1129-2377